Merck Announces Positive Outcome of IIIb Study for Kuvan
Darmstadt, Germany (ots/PRNewswire) - - Primary endpoint met in SPARK study: significant increase in phenylalanine tolerance demonstrated after 26 weeks of the study in children less than 4 years of age with phenylketonuria and responsive to Kuvan treated with Kuvan plus a phenylalanine-restricted diet, versus diet alone - SPARK study was conducted as a post-authorization measure and results will be submitted to EMA this ...